The Down Under medical landscape is abuzz with the introduction of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist showing significant results in clinical trials for managing obesity. https://sparxsocial.com/story612082/the-new-retatrutide-australia-a-potential-prospect-for-obesity-treatment